Table 3. Kaplan-Meier analysis for disease-specific survival stratified for subgroups of gastric cancer patients.
| 5-year cumulative survival (95% CI) | ||||
|---|---|---|---|---|
| Subgroup | All patients | HPA2110-negative | HPA2110-positive | p-value |
| HPA2110 | 36.3 (31.0–41.6) | 43.3 (33.7–52.9) | 24.0 (16.9–31.1) | 0.001 |
| Age, years | ||||
| < 66 | 44.7 (36.9–52.5) | 53.9 (40.8–67.0) | 27.8 (16.8–38.8) | 0.006 |
| ≥66 | 27.5 (20.2–34.8) | 30.2 (16.7–43.7) | 20.7 (11.5–29.9) | 0.103 |
| Gender | ||||
| Male | 33.2 (25.8–40.6) | 43.9 (29.2–58.6) | 16.9 (8.4–25.3) | 0.002 |
| Female | 39.5 (31.7–47.3) | 42.6 (29.7–55.5) | 32.9 (21.3–44.5) | 0.170 |
| Lauréns classification | ||||
| Intestinal | 35.9 (27.5–44.3) | 43.5 (26.4–60.6) | 27.0 (16.8–37.2) | 0.150 |
| Diffuse | 36.7 (29.6–43.8) | 43.1 (31.3–54.9) | 20.6 (10.8–30.4) | 0.001 |
| Stage | ||||
| IA-B | 86.1 (79.0–93.2) | 96.7 (90.2–1.03) | 78.8 (63.7–93.9) | 0.048 |
| II | 40.0 (24.3–55.7) | 41.7 (13.9–69.5) | 32.9 (12.5–53.3) | 0.526 |
| IIIA-B | 13.5 (6.2–20.8) | 30.5 (12.5–53.3) | 6.5 (0–13.6) | 0.005 |
| IV | 3.6 (0–7.5) | 6.4 (0–15.0) | 2.2 (0–6.5) | 0.057 |
| pT-classification | ||||
| pT1 | 87.4 (78.6–96.2) | 95.2 (86.2–1.04) | 80.2 (60.0–1.00) | 0.185 |
| pT2 | 61.5 (48.7–74.2) | 54.1 (28.4–79.8) | 55.5 (33.7–77.3) | 0.960 |
| pT3 | 19.4 (12.7–26.1) | 31.7 (17.8–45.6) | 13.9 (6.0–21.7) | 0.010 |
| pT4 | 2.2 (0–6.1) | 8.7 (0–20.3) | 0 (0–0) | 0.152 |
| pN-classification | ||||
| pN0 | 67.5 (59.7–75.3) | 77.6 (65.3–89.9) | 54.5 (41.2–67.8) | 0.022 |
| pN+ | 9.9 (5.4–14.4) | 17.9 (7.9–27.9) | 4.6 (0.2–8.9) | 0.002 |
| Tumor size, diameter | ||||
| < 5 cm | 55.5 (47.9–63.1) | 69.2 (56.7–81.7) | 36.6 (25.6–47.6) | 0.001 |
| ≥ 5 cm | 12.5 (6.8–18.2) | 17.8 (7.0–28.6) | 8.7 (1.6–15.8) | 0.006 |
| Ploidity | ||||
| Diploid | 40.1 (33.4–46.8) | 48.3 (36.7–59.9) | 24.8 (15.6–34.0) | 0.001 |
| Aneuploid | 14.2 (6.4–22.0) | 17.1 (8.3–33.4) | 13.6 (3.4–23.8) | 0.735 |
| SPF | ||||
| < 7.6 | 47.6 (39.0–56.2) | 54.2 (39.3–69.1) | 33.0 (19.5–46.5) | 0.036 |
| ≥ 7.6 | 19.9 (13.0–26.8) | 31.7 (17.0–46.5) | 12.9 (5.3–20.59 | 0.012 |
| Ki-67 | ||||
| ≤ 10% | 32.3 (22.1–42.5) | 39.6 (23.5–55.7) | 16.1 (2.4–29.8) | 0.060 |
| > 10% | 29.8 (22.5–37.1) | 36.7 (23.0–50.4) | 22.1 (13.7–30.5) | 0.043 |
| p53 | ||||
| ≤ 20% | 41.5 (34.8–48.2) | 49.8 (37.8–61.8) | 28.4 (19.4–37.4) | 0.004 |
| > 20% | 24.7 (15.9–33.5) | 29.4 (13.9–44.9) | 14.0 (3.6–24.4) | 0.071 |
Abbreviations: HPA2110 = polyclonal antibody, CI = confidence interval; SPF = S-phase fraction